The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...

KEY TAKEAWAYS Pfizer said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed ...

KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...

Pfizer ($PFE) became a household name during the pandemic, and its stock rose along with its fame. However, three years later ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...

We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study ... iv Despite its severity, there are no FDA-approved treatments for cachexia. iii About Ponsegromab Ponsegromab ...

Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...